Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Sept 2009

Davids Matthew S, Davids Matthew, Charlton Amanda, Ng Swee-Siang, Chong Mei-Ling, Laubscher Kevin, Dar Mohammed, Hodge Jeffrey, Soong Richie, Goh Boon Cher

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Merkel Cell
Share to Fatal Outcome
Share to Indazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Keratins

Share to Phosphopyruvate Hydratase

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Sulfonamides

Source

Identifiers

PMID: 19564526
DOI: 10.1200/JCO.2009.21.8149

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.PMID 19564526Read ↗

Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.Semantic proximity Read ↗

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.Semantic proximity Read ↗

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.Semantic proximity Read ↗

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma.Semantic proximity Read ↗

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.Semantic proximity Read ↗

Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.Semantic proximity Read ↗

Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.Semantic proximity Read ↗

Complete Response of Anaplastic Lymphoma Kinase-Mutated Refractory Extranodal Natural Killer/T-Cell Lymphoma to Crizotinib.Semantic proximity Read ↗

Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.Semantic proximity Read ↗

Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation.Semantic proximity Read ↗

Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation.Semantic proximity Read ↗

Efficacy of MEK inhibition in patients with histiocytic neoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.